[HTML][HTML] Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Immunotherapies targeting the PD-1 pathway produce durable responses in many cancers,
but the tumor-intrinsic factors governing response and resistance are largely unknown. MHC-
II expression on tumor cells can predict response to anti–PD-1 therapy. We therefore sought
to determine how MHC-II expression by tumor cells promotes PD-1 dependency. Using
transcriptional profiling of anti-PD-1–treated patients, we identified unique patterns of
immune activation in MHC-II+ tumors. In patients and preclinical models, MHC-II+ tumors …
but the tumor-intrinsic factors governing response and resistance are largely unknown. MHC-
II expression on tumor cells can predict response to anti–PD-1 therapy. We therefore sought
to determine how MHC-II expression by tumor cells promotes PD-1 dependency. Using
transcriptional profiling of anti-PD-1–treated patients, we identified unique patterns of
immune activation in MHC-II+ tumors. In patients and preclinical models, MHC-II+ tumors …
[引用][C] Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 2018; 3
DB Johnson, MJ Nixon, Y Wang, DY Wang… - 2018
以上显示的是最相近的搜索结果。 查看全部搜索结果